Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
1 - 10of about 309 News
1 - 10of about 309 News
November 11, 2022
Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for Eylea™ in the EU for treatment of preterm infants with retinopathy of prematurity
READ MORE
November 08, 2022
Third quarter of 2022
Bayer with continued strong performance
READ MORE
October 17, 2022
Not intended for U.S. and UK Media
Bayer expands development program for elinzanetant with Phase III study in breast cancer patients with vasomotor symptoms caused by endocrine therapy
READ MORE
October 05, 2022
Bayer completes sale of its Environmental Science Professional business to Cinven
READ MORE
September 08, 2022
Not intended for U.S. and UK Media
Aflibercept 8 mg first to achieve extended injection intervals of 16 weeks in up to 89% of patients
READ MORE
September 02, 2022
Not intended for U.S. and UK Media
Kerendia™ (finerenone) receives updated label in the U.S. to include findings from Phase III FIGARO-DKD cardiovascular outcomes study
READ MORE
September 01, 2022
Kimberly Mathisen appointed to the Supervisory Board of Bayer AG
READ MORE
August 28, 2022
Not intended for U.S. and UK Media
Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian
READ MORE
August 12, 2022
Bayer statement on the decision in the BASF arbitration proceedings
READ MORE
August 11, 2022
Bayer Showcases Leadership in Breakthrough Innovations and Sustainable, Tailored Solutions to Meet Global Challenges in Agriculture
READ MORE
1 - 10of about 309 News
1 - 10of about 309 News

 

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases
Discover Bayer's Latest Ad-Hoc Releases
read more